Literature DB >> 23423815

Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.

Tamar Tadmor1, Lev Shvidel, Ariel Aviv, Rosa Ruchlemer, Osnat Bairey, Mona Yuklea, Yair Herishanu, Andre Braester, Naomi Rahimi-Levene, Naomi Levene, Fiona Vernea, Jonathan Ben-Ezra, Jacob Bejar, Aaron Polliack.   

Abstract

BACKGROUND: Bone marrow (BM) biopsies from patients with chronic lymphocytic leukemia (CLL) may show reticulin fibrosis at diagnosis, but its significance remains unclear. This study sought to assess the prognostic impact of BM reticulin fibrosis in patients with previously untreated CLL.
METHODS: Data was reviewed from untreated CLL patients in the national Israel CLL database, followed during 1987 to 2012. All bone marrow biopsies were graded for reticulin fibrosis using a modified scoring system containing 4 grades (0-3), based on the European consensus report. Grade of reticulin fibrosis was correlated with overall survival (OS), outcome, and a number of well-recognized prognostic factors for CLL.
RESULTS: The final cohort included 176 patients (122 males and 51 females). Median age was 63 years (range, 32-86 years) and the 5-year OS was 77.1%. Grade of BM reticulin fibrosis correlated with OS (P < .0001) and mortality (P = .001), and separated patients into 2 groups with different survival curves. Advanced reticulin fibrosis (grades 2-3) was associated with thrombocytopenia (platelet counts of < 100,000/mm(3) ) (P = .025), anemia (P = .018), elevated β2-microglobulin < 4000 μg/mL (P = .048), and the presence of 11q deletion (P = .0015).
CONCLUSIONS: There was a significant correlation between poor survival and grade of BM reticulin fibrosis. This staining procedure is easy to perform and can readily be added routinely when examining BM biopsies in CLL, because the findings do have prognostic implications.
Copyright © 2013 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23423815     DOI: 10.1002/cncr.27930

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.

Authors:  Uri Rozovski; Ivo Veletic; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Taghi Manshouri; Alessandra Ferrajoli; Jan A Burger; Prithviraj Bose; Phillip A Thompson; Nitin Jain; William G Wierda; Srdan Verstovsek; Michael J Keating; Zeev Estrov
Journal:  J Immunol       Date:  2022-05-20       Impact factor: 5.426

2.  Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.

Authors:  Gabriele Todisco; Taghi Manshouri; Srdan Verstovsek; Lucia Masarova; Sherry A Pierce; Michael J Keating; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2015-10-19

Review 3.  Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.

Authors:  Abdallah Abou Zahr; Mohamed E Salama; Nicole Carreau; Douglas Tremblay; Srdan Verstovsek; Ruben Mesa; Ronald Hoffman; John Mascarenhas
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941

4.  Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases.

Authors:  Francesco Angotzi; Andrea Visentin; Federico Scarmozzino; Alessandro Cellini; Roberta Bertorelle; Marco Pizzi; Gianni Binotto; Angelo Paolo Dei Tos; Livio Trentin
Journal:  Curr Oncol       Date:  2022-02-27       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.